Hepatorenal syndrome: nursing assessment and interventions

Hepatorenal syndrome (HRS) is a form of acute kidney injury that develops in patients with advanced cirrhosis and ascites. The kidneys themselves are structurally normal — the injury is functional, driven by extreme renal vasoconstriction in response to splanchnic vasodilation. Without treatment, HRS type 1 (now called HRS-AKI) carries a median survival of approximately two weeks. Recognizing the early signs, understanding the diagnostic workup (including the albumin challenge), and monitoring vasoconstrictor therapy are essential nursing competencies for any hepatology, ICU, or med-surg rotation involving liver patients.

Pathophysiology: the splanchnic vasodilation model

HRS develops through a well-characterized hemodynamic cascade that begins with portal hypertension and ends with renal vasoconstriction. Understanding this sequence connects the pathophysiology directly to the treatment rationale.

Portal hypertension and splanchnic vasodilation. Cirrhosis increases intrahepatic vascular resistance, raising portal pressure. The splanchnic vascular bed responds by overproducing vasodilators — primarily nitric oxide and prostaglandins. This causes progressive splanchnic arterial vasodilation, which pools blood in the mesenteric circulation and reduces effective arterial blood volume. The result is systemic arterial underfilling despite a normal or even expanded total blood volume. This is the underfilling hypothesis, which remains the dominant explanatory model for HRS.

Compensatory neurohormonal activation. The body detects the reduced effective blood volume and activates three compensatory systems: the renin-angiotensin-aldosterone system (RAAS), the sympathetic nervous system (SNS), and arginine vasopressin (ADH). In early cirrhosis, these systems maintain renal perfusion adequately. As cirrhosis progresses, the vasodilation overwhelms the compensatory response. Cardiac output, which initially increases to compensate, eventually declines in advanced disease — a phenomenon called cirrhotic cardiomyopathy.

Renal vasoconstriction. The activated RAAS and SNS cause intense renal arterial vasoconstriction. Renal blood flow drops, glomerular filtration rate (GFR) falls, and the kidneys avidly retain sodium and water. Critically, the renal parenchyma remains structurally intact — there is no tubular necrosis, no glomerular disease, and no obstruction. This functional nature is what distinguishes HRS from other causes of AKI in cirrhosis.

Bacterial translocation and systemic inflammation. Gut bacterial translocation — where bacteria or bacterial products (endotoxins, PAMPs) cross the intestinal barrier into the portal and systemic circulation — plays a major amplifying role. Systemic inflammatory response syndrome (SIRS) is present in almost half of HRS-AKI patients. Elevated interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) worsen splanchnic vasodilation and further impair renal perfusion. This is why infections — particularly spontaneous bacterial peritonitis (SBP) — are the most common trigger for HRS. The overflow theory, an alternative model, proposes that renal sodium retention is a primary hepatorenal reflex rather than a response to underfilling, though it has less clinical support than the underfilling hypothesis.

Classification: HRS-AKI and HRS-NAKI

The International Club of Ascites (ICA) revised the HRS classification in 2015 and further refined it in subsequent EASL guidance. The old “type 1 and type 2” terminology has been replaced with a system aligned to modern acute kidney injury definitions.

HRS-AKI (formerly HRS type 1)

HRS-AKI is defined by a rapid decline in kidney function meeting standard AKI criteria:

• Serum creatinine rise of 0.3 mg/dL or more within 48 hours, OR
• Serum creatinine rise of 50% or more from baseline within 7 days

The previous requirement that creatinine must exceed 2.5 mg/dL has been eliminated. Under the updated criteria, HRS-AKI can be diagnosed at lower creatinine levels, allowing earlier intervention. HRS-AKI stages further into 1A (creatinine below 1.5 mg/dL) and 1B (creatinine 1.5 mg/dL or above), which helps guide treatment intensity.

Prognosis. Without treatment, median survival is approximately 2 weeks. With vasoconstrictor therapy plus albumin, response rates range from 40% to 50%, and responders have significantly improved transplant candidacy.

HRS-NAKI (formerly HRS type 2)

HRS-NAKI encompasses functional renal impairment that does not meet AKI criteria. It subdivides into:

• HRS-AKD (acute kidney disease): eGFR below 60 mL/min/1.73 m² for less than 3 months
• HRS-CKD (chronic kidney disease): eGFR below 60 mL/min/1.73 m² for 3 months or longer

HRS-NAKI patients typically present with moderate, stable renal impairment and refractory ascites as their dominant clinical problem. The course is more indolent, with median survival of 3 to 6 months. However, HRS-NAKI can progress to HRS-AKI at any time, particularly when an acute precipitant (infection, bleeding, overdiuresis) occurs.

Diagnostic criteria

The updated ICA diagnostic criteria require all of the following:

1. Cirrhosis with ascites (acute or chronic liver disease)
2. AKI diagnosis — serum creatinine increase of 0.3 mg/dL or more within 48 hours, or 50% or more increase within 7 days
3. No improvement after volume expansion — diuretics withdrawn for at least 48 hours, plus albumin given at 1 g/kg/day (maximum 100 g/day) for 2 consecutive days, with no sustained reduction in serum creatinine
4. Absence of shock (no ongoing hemodynamic instability requiring vasopressors for a non-HRS indication)
5. No current or recent nephrotoxic drugs — including NSAIDs, aminoglycosides, iodinated contrast, and vancomycin at supratherapeutic levels
6. No evidence of structural kidney disease — proteinuria below 500 mg/day, fewer than 50 RBCs per high-power field on urinalysis, and normal renal ultrasound

The albumin challenge (criterion 3) is the critical diagnostic step. It serves a dual purpose: it rules out prerenal azotemia (which will respond to volume expansion) and it initiates the therapeutic albumin that HRS patients need. If creatinine improves with albumin alone, the diagnosis is volume-responsive AKI, and vasoconstrictor therapy is unnecessary.

Precipitating factors

Most HRS-AKI episodes have an identifiable trigger. Treating the precipitant is essential — vasoconstrictor therapy alone will fail if the underlying cause persists.

Nursing assessment

Structured assessment in patients at risk for or diagnosed with HRS centers on hemodynamic status, fluid balance, renal function trends, and infection surveillance.

Urine output. This is the single most important bedside parameter. Insert a Foley catheter for accurate measurement. Urine output below 500 mL/day raises concern; below 200 mL over 8 hours is an urgent red flag requiring immediate provider notification. Document hourly urine output in ICU settings and every 4 hours on the floor.

Daily weight. Weigh at the same time daily, in the same clothing, on the same scale. Rapid weight gain despite oliguria suggests worsening ascites and third-spacing rather than true volume overload. Weight trends guide diuretic management and paracentesis timing.

Strict intake and output. Record all oral, IV, and albumin fluid intake against all output (urine, paracentesis volumes, estimated insensible losses). A negative fluid balance in an oliguric HRS patient may indicate excessive diuresis and must be flagged.

Renal labs. Track serum creatinine at minimum every 24 hours (more frequently in HRS-AKI). A rising creatinine after the albumin challenge confirms the diagnosis. Also monitor BMP (BUN, potassium, sodium, bicarbonate), as electrolyte derangements are common.

Urine sodium. A urine sodium below 10 mEq/L is characteristic of HRS and helps distinguish it from acute tubular necrosis (ATN), where urine sodium is typically above 20 mEq/L. Fractional excretion of sodium (FENa) below 1% further supports HRS over ATN.

Infection surveillance. Because infection is the most common precipitant, actively monitor for signs of SBP (fever, abdominal pain, worsening encephalopathy in a patient with ascites), UTI, pneumonia, and cellulitis. Any new infection in a cirrhosis patient with renal impairment should raise suspicion for HRS.

Mental status. HRS often coexists with hepatic encephalopathy. Perform regular orientation checks and assess for asterixis. Worsening encephalopathy in a patient with rising creatinine suggests either infection as a shared precipitant or uremic encephalopathy on top of hepatic encephalopathy.

Ascites assessment. Measure abdominal girth daily. Increasing ascites with declining urine output is a hallmark of HRS-NAKI progressing to HRS-AKI. Document shifting dullness and fluid wave findings.

Priority nursing interventions

SBP prophylaxis and early treatment

SBP prevention is HRS prevention. In patients with ascites and prior SBP episodes, ensure prophylactic antibiotics are ordered — norfloxacin 400 mg daily or trimethoprim-sulfamethoxazole (one double-strength tablet daily) are standard regimens. When SBP is diagnosed, IV albumin must be given alongside antibiotics: 1.5 g/kg on day 1 and 1 g/kg on day 3. This albumin protocol has been shown to reduce HRS incidence and mortality in SBP patients.

Albumin administration

Albumin serves multiple roles in HRS management beyond simple volume expansion. It binds endotoxins, has anti-inflammatory properties, and supports cardiac output in the underfilled circulatory state. During the diagnostic albumin challenge, administer 1 g/kg/day (maximum 100 g/day) for 2 days. For ongoing HRS treatment alongside vasoconstrictors, the dose is typically 20 to 40 g IV daily.

Nursing considerations for albumin infusion:

• Use 25% albumin (concentrated) to minimize total fluid volume in patients who are already fluid-overloaded with ascites
• Monitor for pulmonary edema — auscultate lung sounds before and during infusion; patients with concurrent cardiac dysfunction or volume overload are at highest risk
• Monitor blood pressure during infusion — albumin draws fluid intravascularly and can transiently raise BP
• Check for allergic reactions (rare with human albumin but possible)
• Infuse over 2 to 4 hours for therapeutic doses; faster rates increase risk of volume overload

Vasoconstrictor therapy monitoring

Vasoconstrictors are the cornerstone of HRS-AKI pharmacotherapy. They work by constricting the dilated splanchnic circulation, redirecting blood flow to the kidneys. Three regimens are used depending on setting and availability.

Terlipressin (Terlivaz). FDA-approved in September 2022 — the first medication specifically approved for HRS. It is a vasopressin V1 receptor agonist that selectively constricts splanchnic vasculature.

• Dosing: 0.85 mg IV every 6 hours (FDA-approved dosing) or 0.5 to 1 mg IV every 4 to 6 hours (European dosing). If serum creatinine has not decreased by 25% or more after 3 days, the dose can be increased to a maximum of 2 mg every 4 to 6 hours.
• Maximum duration: 14 days
• Monitoring: Continuous cardiac monitoring for ischemic complications. Assess peripheral perfusion every 2 to 4 hours (check capillary refill, skin color, temperature of extremities). Monitor pulse oximetry — respiratory failure was the most significant safety signal in the CONFIRM trial (15.5% in the terlipressin group vs 7.1% with placebo). Watch for abdominal pain, diarrhea, and nausea (common side effects).
• Contraindications: Coronary artery disease, peripheral vascular disease, pregnancy, baseline hypoxia (SpO2 below 90%), and serum creatinine above 5 mg/dL (unlikely to respond)
• CONFIRM trial results: 29% of patients achieved HRS reversal (defined as creatinine returning to 1.5 mg/dL or below on two consecutive days) compared to 16% with placebo

Norepinephrine. The ICU alternative to terlipressin, used when terlipressin is unavailable or when the patient requires ICU-level monitoring.

• Dosing: 0.5 to 3 mg/hour continuous IV infusion via central line
• Target: Increase mean arterial pressure (MAP) by 10 mmHg from baseline
• Monitoring: Continuous arterial blood pressure monitoring (arterial line preferred), hourly urine output, central venous access is mandatory, assess for peripheral and digital ischemia
• Response rates: 39% to 70% in clinical studies, comparable to terlipressin

Midodrine plus octreotide. The non-ICU or outpatient option, used when neither terlipressin nor norepinephrine is available or appropriate.

• Midodrine: 7.5 to 12.5 mg orally three times daily. Titrate to achieve a 15 mmHg increase in MAP
• Octreotide: 100 to 200 mcg subcutaneously three times daily (or 25 to 50 mcg/hour continuous IV)
• Monitoring: Blood pressure before each midodrine dose (hold if supine systolic BP exceeds 160 mmHg), heart rate (octreotide can cause bradycardia), blood glucose (octreotide can suppress insulin secretion)
• Response rate: Approximately 40%, lower than terlipressin or norepinephrine

Nephrotoxin avoidance

Maintain an active nephrotoxin list for every cirrhotic patient. NSAIDs, aminoglycosides (gentamicin, tobramycin), iodinated contrast agents, and high-dose vancomycin must be flagged and, when possible, avoided. If contrast is necessary, ensure adequate pre-hydration and consider using the lowest possible contrast volume. Advocate for non-nephrotoxic antibiotic alternatives (e.g., ceftriaxone for SBP instead of aminoglycosides).

TIPS consideration

Transjugular intrahepatic portosystemic shunt (TIPS) may be considered when medical therapy fails. By creating a shunt between the portal and hepatic veins, TIPS reduces portal pressure and improves effective arterial volume. However, it carries a risk of worsening hepatic encephalopathy and is contraindicated in patients with severe hepatic dysfunction (Child-Pugh score above 12, bilirubin above 5 mg/dL). The role of TIPS in HRS remains under active investigation.

Prognosis and liver transplantation

HRS prognosis depends on the type and treatment response:

• HRS-AKI without treatment: Median survival approximately 2 weeks
• HRS-AKI with vasoconstrictor therapy + albumin: Responders have significantly improved short-term survival and transplant candidacy; non-responders still carry very high mortality
• HRS-NAKI: Median survival 3 to 6 months; often dominated by refractory ascites and recurrent complications
• Post-liver transplant: Renal function frequently recovers because the underlying hemodynamic derangement resolves once a functioning liver restores normal splanchnic and systemic vascular tone

Liver transplantation as definitive treatment

Liver transplantation is the only curative treatment for HRS. All HRS patients should be evaluated for transplant candidacy if they do not have absolute contraindications. The goal of vasoconstrictor therapy is to stabilize renal function as a bridge to transplantation — patients who respond to medical therapy have better post-transplant outcomes than those who arrive at transplant on kidney replacement therapy.

Simultaneous liver-kidney transplant (SLK)

Current US policy (OPTN/UNOS criteria) recommends simultaneous liver-kidney transplant when:

• Sustained AKI with kidney replacement therapy required for 6 weeks or longer
• eGFR of 25 mL/min/1.73 m² or below for 6 weeks or longer
• CKD with eGFR below 60 for more than 90 days combined with a kidney biopsy showing greater than 30% glomerulosclerosis or interstitial fibrosis

For patients who receive a liver-only transplant, a “safety net” policy allows prioritized access to a kidney transplant within 60 to 90 days if renal function does not recover.

NCLEX clinical decision priorities

These high-yield scenarios test the clinical reasoning skills that NCLEX emphasizes for hepatorenal syndrome:

1. A cirrhotic patient with ascites develops oliguria and rising creatinine. The first nursing action is to assess for infection (check temperature, obtain blood cultures, prepare for diagnostic paracentesis) and hold diuretics — infection is the most common precipitant, and diuretics worsen renal hypoperfusion.

2. Urine sodium returns at 8 mEq/L in a cirrhotic patient with AKI. This finding suggests hepatorenal syndrome rather than acute tubular necrosis, because HRS causes intense sodium retention (urine Na below 10 mEq/L), while ATN typically shows urine Na above 20 mEq/L.

3. A patient receiving terlipressin reports chest tightness and new-onset dyspnea. The priority action is to obtain a pulse oximetry reading, hold the next terlipressin dose, and notify the provider immediately — respiratory failure and myocardial ischemia are the most serious terlipressin adverse effects.

4. During a diagnostic albumin challenge (1 g/kg/day for 2 days), the patient’s creatinine decreases from 2.1 to 1.4 mg/dL. This means the patient does not have HRS — they had volume-responsive prerenal AKI. Vasoconstrictor therapy is unnecessary. Continue supportive management.

5. A cirrhotic patient is scheduled for large-volume paracentesis of 8 liters. The nurse should ensure that albumin replacement is ordered (6 to 8 g per liter removed = 48 to 64 g of albumin) to prevent post-paracentesis circulatory dysfunction, a known HRS precipitant.

6. A patient on midodrine/octreotide has a supine systolic blood pressure of 170 mmHg before the next dose. The nurse should hold the midodrine dose, notify the provider, and reassess in 1 hour — supine hypertension is a sign of overcorrection and risks end-organ ischemia.

7. The physician orders ketorolac (NSAID) for pain in a patient with cirrhosis and borderline renal function. The nurse should question the order and recommend a non-nephrotoxic alternative — NSAIDs inhibit prostaglandin-mediated renal vasodilation, which is a critical compensatory mechanism in cirrhotic patients, and are a known HRS precipitant.

8. A patient with HRS-AKI who responded to terlipressin + albumin is being evaluated for transplant. The nurse understands that the goal of vasoconstrictor therapy was to bridge the patient to transplantation in better condition — liver transplant is the only curative treatment, and responders to medical therapy have improved post-transplant outcomes compared to non-responders.